Skip to main content
森萱医药 logo

森萱医药 — Investor Relations & Filings

Ticker · 920946 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 417 across all filing types
Latest filing 2025-11-05 Call Transcript
Country CN China
Listing Beijing Stock Exchange 920946

About 森萱医药

https://www.senxuan.cn/

Jiangsu Senxuan Pharmaceutical Co., Ltd. specializes in the research, development, and production of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and specialized fine chemicals. The company’s product portfolio includes key intermediates for antiviral medications, such as those used in the treatment of HIV, and anticonvulsant agents like Primidone. Additionally, it produces high-purity chemical solvents including 1,4-dioxane and 1,3-dioxolane for diverse industrial applications. Senxuan Pharmaceutical maintains a focus on advanced chemical synthesis and large-scale manufacturing capabilities, adhering to international quality standards to support the global life sciences and chemical sectors. Its operations are characterized by a commitment to technical innovation and the supply of critical chemical building blocks for complex therapeutic formulations.

Recent filings

Filing Released Lang Actions
2025年第三季度报告业绩说明会预告公告
Call Transcript Classification · 90% confidence The document is an announcement for a 2025 third quarter earnings performance explanation meeting (业绩说明会预告公告). It references the previously published 2025 third quarter report (公告编号：2025-095) but does not contain the actual financial data or detailed financial statements itself. The document invites investors to participate in a conference call/webinar to discuss the quarterly results. The document length is short (1274 characters) and it primarily serves as a notice for the upcoming earnings call rather than the earnings release itself. According to the classification rules, such announcements about earnings calls or performance explanation meetings are best classified as Call Transcript (CT) if the transcript is included, or if it is only a notice of the call, it is closer to an Investor Presentation (IP) or Regulatory Filing (RNS). However, since this is a pre-announcement of the earnings explanation meeting and not the transcript or presentation itself, and it is not a simple report publication announcement, the best fit is Call Transcript (CT) category as it relates to the earnings call event. Confidence is high given the clear description of the event and its nature.
2025-11-05 Chinese
2025年三季度报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as the "2025 Third Quarter Report" of Jiangsu Senxuan Pharmaceutical Co., Ltd. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and explanations of significant changes in financial data. The report covers the period ending September 30, 2025, and includes comparative data from previous periods. It explicitly states it is a quarterly report and is unaudited. The content is comprehensive and includes management's discussion of financial results, business conditions, and outlook. This matches the definition of an Interim / Quarterly Report (IR). The document length is substantial (15,000 characters), and it contains actual financial statements and substantive financial data, not just an announcement or summary. Therefore, the correct classification is IR with high confidence. 9M 2025
2025-10-28 Chinese
第四届董事会第十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is titled as a resolution announcement from the company's fourth board of directors meeting. It details the meeting date, attendance, and voting results on several agenda items, including approval of the third quarter report, changes to the business scope and company bylaws, and the calling of an extraordinary shareholders meeting. The document references other filings where the full reports or notices are published but does not itself contain the full financial report or detailed financial data. It is a formal announcement of board meeting resolutions rather than the report itself. The document length is short (1744 characters), and it serves as an official announcement of board decisions. Therefore, it fits best under Board/Management Information (MANG).
2025-10-28 Chinese
关于召开2025年第三次临时股东会通知公告（提供网络投票）
Regulatory Filings Classification · 95% confidence The document is a notice announcing the convening of the company's 2025 third extraordinary general meeting of shareholders (临时股东会通知公告). It details the meeting date, voting methods (onsite and online), agenda items, registration procedures, and other logistical information. There is no financial data, earnings, or report content included. The document is relatively short (3214 characters) and serves as an announcement for the meeting rather than the meeting minutes or voting results. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or Proxy Solicitation & Information Statement (PSI). However, since it is a notice of the meeting itself and not the solicitation materials or voting results, it is best classified as a Regulatory Filing (RNS) as a general regulatory announcement. The document does not fit other categories such as Annual Report, Interim Report, or Earnings Release. Given the content and length, the best classification is Regulatory Filings (RNS).
2025-10-28 Chinese
关于拟变更经营范围并修订《公司章程》公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Jiangsu Senxuan Pharmaceutical Co., Ltd. regarding a proposed change in the company's business scope and amendments to the Articles of Association. It includes details about the revisions to the company's registered business activities and governance documents, and mentions that these changes will be submitted to the shareholders' meeting for approval. The document does not contain financial statements, audit information, or detailed financial data. It is a regulatory announcement about corporate governance and business scope changes, not a full report or financial filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-10-28 Chinese
江苏世纪同仁律师事务所关于江苏森萱医药股份有限公司2025年第二次临时股东会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 85% confidence The document is a legal opinion letter from a law firm on the legality and validity of the 2025 second extraordinary shareholders’ meeting (an EGM) of 江苏森萱医药股份有限公司. It provides detailed voting results for multiple proposals. This fits the definition of “Declaration of Voting Results & Voting Rights Announcements” (DVA).
2025-09-15 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.